Drug intelligence / Profile preview

Nal-Glu

Development stage: Unknown
Lead developer: Salk Institute for Biological Studies
Modality: Peptides, Small Molecules
Administration: Subcutaneous, Intramuscular

Overview

Nal-Glu is a synthetic peptide and potent gonadotropin-releasing hormone (GnRH) receptor antagonist. It was developed to acutely inhibit the action of endogenous GnRH by competitively blocking its receptor (GnRHR), thereby suppressing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This results in inhibition of ovulation in women and suppression of spermatogenesis in men. Nal-Glu has been studied for use as a contraceptive agent and for investigating reproductive endocrinology. Its development was discontinued due to challenges with synthesis cost, delivery, and side effects compared to newer antagonists[1][2][4][5].

Other names: gonadotropin-releasing hormone antagonistFactryl

Targets

GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on Nal-Glu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nal-Glu.

Explore the full profile